Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CEPH - CEPHALON -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (9)	5/7/2002 2:36:02 AM
From: Doc Bones	Respond to of 109

Cephalon Narrows Its Loss on Strong Provigil Sales [TSCM] By Adam Feuerstein Staff Reporter 05/06/2002 06:49 PM EDT Cephalon (CEPH:Nasdaq - news - commentary - research - analysis) Monday reported a loss that narrowed over the year-ago quarter, as higher drug sales were tempered by a host of one-time charges. The West Chester, Penn.-based biotech firm posted a net loss of $2.9 million, or 5 cents a share, in the first quarter, compared with a net loss of $11.8 million, or 28 cents a share, a year ago. Excluding a host of charges and one-time items, Cephalon earned $14.3 million, or 25 cents a share. Analysts were expecting the company to earn 15 cents a share, according to Thomson Financial/First Call. Cephalon, as expected, took a $7.1 million charge in the quarter related to the end of a sales and marketing joint venture tied to its antisleepiness drug, Provigil. Total revenue in the quarter reached $111.5 million, including $95 million in product sales. First-quarter Provigil sales rose 64% to $44.2 million, compared with the year-ago quarter. The drug is approved for patients suffering from narcolepsy, but a majority of sales are derived off-label for people who battle daytime sleepiness related to a wide range of illnesses. Cephalon is conducting clinical studies seeking Food and Drug Administration approval for expanded uses of the drug. Looking ahead, Cephalon said it expects to earn 20 cents in the second quarter, a penny above the current Wall Street consensus estimate. Full-year 2002 earnings are expected to reach a range of $1.05 to $1.08 a share. Analysts are expecting earnings of $1.09 a share. Cephalon closed Monday down $4.34, or 7%, to $54.95. thestreet.com